Clinical trial
Chidamide Plus DCAG for Relapsed/Refractory AML
NCT02886559 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Chidamide Plus DCAG for Relapsed/Refractory AML
- Lead sponsor
- Chinese PLA General Hospital
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- June 30, 2016
- Completion date
- June 30, 2019
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
aml, relapse